Several antimitotic, tubulin-binding agents, such as colchicine, colcemid, and podophyllotoxin, inhibit the capping of fluorescent-labeled concanavalin A in Chinese hamster ovary cells. By comparing the effects of these agents on parental cell lines and on several independently selected colchicine-resistant mutants with decreased drug permeability, we have demonstrated that permeation of these drugs is required for inhibition of capping. These data suport the hypothesis that these antimitotic agents interact with an intracellular component, probably microtubules, to prevent the directional movement of concanavalin A receptors on the surface membranes of Chinese hamster ovary cells.
Various cell surface receptors, such as those for the mitogenic plant lectins, concanavalin A (Con A) and phytohemagglutinin, exhibit the ability to move in the lipid membrane bilayer. This movement is characterized by two distinct steps involving the redistribution of randomly oriented receptors into clusters or patches and subsequently into one large aggregate or cap. The phenomenon of cap formation has contributed to the current concept of the mammalian cell membrane as being composed of receptors and other surface components that are mobile in the fluid lipid phase (1, 2) .
Recently it has been shown that the antimitotic agent colchicine, thought to specifically bind microtubule subunits, can alter the redistribution of certain membrane receptors, including those for Con A (3) (4) (5) (6) (7) (8) (9) (10) . Various drugs that also bind the tubulin subunits of microtubules, for example, colcemid, vinblastine, vincristine, and podophyllotoxin, elicit very similar responses, whereas a nonbinding analogue of colchicine, lumicolchicine, does not (3) . These kinds of observations have led Edelman and coworkers (3) (4) (5) and others (6) (7) (8) (9) (10) to postulate that the nonrandom motion of some cell surface receptors is directed and modulated by a submembranellar cytoplasmic network, composed of microtubules and possibly other fibrous components. While the specificity of various antimitotic drugs to interact with microtubules has not been rigorously challenged, there is as yet little concrete evidence that it is the action of these agents on an intracellular microtubule structure that subsequently results in their effect on capping. As an alternative possibility, these drugs may be acting on the surface membrane modulating the lipid fluidity and thus affecting capping. In support of this hypothesis it has been pointed out that there exist other classes of compounds that inhibit capping, for example, certain local anesthetics and tranquilizers (11) which are known to interact with the cell membrane itself (12) . Furthermore, the action of colchicine directly at a membrane level (inhibition of nucleoside transport) has also been reported (13) and is thought to be independent of any action on microtubules. Also, in at least some systems, rather high concentrations of antitubulin drugs are required to elicit a response, concentrations higher than those thought necessary for antimitotic effects. In light of these limitations, we decided to investigate the basic question of whether or not antimitotic agents are required to enter the cell to affect Con A capping.
Previously we have isolated and characterized a class of colchicine-resistant mutants in Chinese hamster ovary (CHO) cells that have greatly reduced permeability to colchicine and other compounds (14, 15, 21) . The availability of these membrane-altered mutants allows us to pose the fundamental question of whether or not cell permeation is required for colchicine and a number of other agents to affect Con A capping in CHO cells. In this study, we report on the effects of drugs on capping of fluorescent Con A (fl-Con A) in parental and colchicine-resistant (CHR) CHO cells.
MATERIALS AND METHODS
Cell Culture Conditions. The parental cell line, AUX B1, and colchicine-resistant (CHR) lines, CHR2HA, CHRC4, and CHRC5, were grown routinely at 370 in suspension cultures in a-minimal essential medium (16) supplemented with 10% fetal calf serum (Flow Laboratories) as described (14) .
Capping of fl-Con A. In preparation for capping, cells were seeded at (14) . Since it is known that the relative rate of colchicine uptake in these mutants is correlated with their relative resistance to colchicine, we reasoned that if colchicine permeability is important for inhibition of Con A capping, there should be also some relationship between the concentration of colchicine required for capping inhibition and the degree of colchicine resistance in these cells. That such a relationship exists is shown in Table 1 , where it can be seen that with the substantially less resistant CHR2HA cells, less colchicine is required to inhibit capping, while another highly resistant line, CHRC4, selected independently from CHRC5, requires a much higher dose.
We have previously observed that nonionic detergents at nontoxic doses increase the rate of colchicine uptake into CHO cells (14; Carlsen, unpublished observation). Thus, to further test that permeation of colchicine is required for the inhibition of capping, we examined the effect of a nonionic detergent, Triton X-100, on the dose response of colchicine inhibition in AUX B1 cells. For this experiment, we chose a concentration of Triton X-100 (1.0 ,g/ml) that stimulates the rate of colchicine uptake by 2-fold in AUX B1 cells (Carlsen, unpublished data) but which by itself has no effect on capping. As can be seen in Fig. 3 Concentration of drug required for inhibition of capping to 50% of the value obtained in the absence of drug was determined from dose-response curves, as shown for AUX B1 and CHRC5 in Fig. 1 . Values for drug resistance were from Ling and Thompson (14) .
ruptive drugs should also inhibit fl-Con A capping in CHO cells. Thus we determined whether or not inhibition of Con A capping is also demonstrated by two other microtubuleactive agents, podophyllotoxin (17) and colcemid, a close analogue of colchicine, and by lumicolchicine (18), a photodegradation product of colchicine that does not bind tubulin. In addition, we were able to determine whether or not permeation of these compounds is required also for inhibition of Con A capping in the same manner as that described for colchicine in Fig. 2 . This was possible since colchicine-resistant cells are cross-resistant to various drugs, e.g., actinomycin D, puromycin, colcemid, and podophyllotoxin (14, 21) , and the resistance to these drugs also results from reduced permeability since it has been demonstrated previously that the mutant cells were less permeable to labeled puromycin and colcemid (15; Carlsen and Ling, unpublished observation). The results of these experiments are summarized in Table 2 . It is seen that both colcemid and podophyllotoxin are able to inhibit Con A capping in AUX B1 cells at very low concentrations: 7 X 10-9 M and 3 X 10-8 M, respectively, while lumicolchicine has no effect up to 10-4 M. Moreover, it is observed from Table 2 that the drug-resistant mutant required substantially higher concentrations of colcemid and podophyllotoxin to inhibit capping than the parental cell line, implying that the permeation of these antimicrotubule drugs also is required to inhibit capping of Con A. These results are completely compatible with the concept of microtubule involvement in Con A capping in CHO cells.
DISCUSSION
The effect of antimitotic agents on Con A capping has been used to support the hypothesis that a cytoplasmic network of microtubules modulates the movement of some cell surface receptors (3) (4) (5) (6) (7) (8) (9) (10) . Very little definitive evidence has been presented that would prove the notion that it is the action of these drugs on the microtubules themselves which is causing the effect on capping. In this report, we have presented several lines of evidence that demonstrate that microtubule-disrupting drugs must get inside the cell to be effective in the inhibition of Con A capping in CHO cells and support the concept that these drugs interfere with capping as a result of their specific interaction with intracellular microtubules.
First, we have shown that the concentration of colchicine required to inhibit Con A capping correlates with the degree of reduced drug permeability in a number of independently selected mutant lines ( The concentration of drug required for 50% inhibition of capping was determined as described in Table 1. colchicine is stimulated by 2-fold by a concentration of Triton X-100 that by itself has no effect on capping, effective inhibitory doses of colchicine shift to lower concentrations by approximately 2-fold (Fig. 3) . Third, cell permeation is required also for two other tubulin-binding agents, colcemid and podophyllotoxin, to inhibit Con A capping. A nonbinding colchicine analogue, lumicolchicine, had no effect ( Table 2) .
There is one additional observation which leads further support to these lines of evidence. As mentioned above, colchicine and colcemid have been reported to exert some influence on at least one other membrane function, that of nucleoside transport, in a manner that does not involve their binding to microtubule components. This function is not altered in the colchicine-resistant mutants; that is, when colchicine inhibition of nucleoside transport is studied, inhibitory doses of colchicine are the same for mutant and parental cell lines (Carlsen, unpublished data). This latter observation suggests that at least some membrane sites must be as accessible in the mutant cells as in parental cells and argues against some alteration in the mutant cells which prevents colchicine from approaching the cell surface per se. Thus, assuming that the plasma membranes of both cell lines are equally accessible to colchicine, one would not expect the observed large concentration difference required to inhibit the capping in these lines (Table 1) if the cell surface were in fact the colchicine target for this effect. This provides some indirect evidence that inhibition of Con A capping in CHO cells by colchicine is not the result of an interaction of the drug with the cell surface membrane.
We believe that all the above data provide some definitive evidence that interaction with an intracellular target is required for inhibition of Con A capping in CHO cells by the antimitotic agents and are consistent with the hypothesis that directional receptor motion in mammalian cells is modulated by a cytoplasmic component, probably the microtubules.
It is of interest to compare the characteristics of Con A capping in CHO cells to those in a number of other cell types. As documented above, Con A forms a central cap which is inhibited by colchicine. We have observed also that other cells, e.g., hamster embryo fibroblasts and mouse L cells, behave similarly (Aubin, unpublished data). However, in contrast to these cells, lymphocytes form polar Con A caps and their formation is stimulated by colchicine and other tubulin-binding agents (3-5, 9, 10 or not permeation is required for antimitotic agents to inhibit the phenomenon of Con A capping in CHO cells. Success in obtaining mutants altered in their intracellular colchicinebinding proteins or in the process of capping itself will greatly facilitate further delineation of this complex capping process and understanding of the intricacies of the cell membrane.
